Insulet Corporation

Equities

PODD

US45784P1012

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
181.1 ^USD	-0.94%		+0.29%	-16.55%

May. 14	Insulet Shares Rise Despite Blue Orca's Short Position	MT
May. 10	Raymond James Adjusts Price Target on Insulet to $213 From $218	MT

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

May 09, 2024 at 04:01 pm EDT

Insulet Corporation revised earnings guidance for the year ending December 31, 2024. For the year ending December 31, 2024, the company is raising its expected revenue growth to a range of 14% to 18% (previously 12% to 17%).

Latest news about Insulet Corporation

Insulet Shares Rise Despite Blue Orca's Short Position	May. 14	MT
Raymond James Adjusts Price Target on Insulet to $213 From $218	May. 10	MT
Wolfe Research Raises Price Target on Insulet to $205 From $200	May. 10	MT
Canaccord Genuity Adjusts Price Target on Insulet to $234 From $226	May. 10	MT
Jefferies Raises Price Target on Insulet to $260 From $255	May. 10	MT
Stifel Adjusts Price Target on Insulet to $185 From $208	May. 10	MT
Insulet misses first-quarter profit estimates as marketing costs weigh	May. 09	RE
Insulet Q1 Earnings, Revenue Rise; 2024 Revenue Growth Boosted	May. 09	MT
Transcript : Insulet Corporation, Q1 2024 Earnings Call, May 09, 2024	May. 09
Earnings Flash (PODD) INSULET CORPORATION Reports Q1 Revenue $441.7M, vs. Street Est of $423.5M	May. 09	MT
Insulet Raises Full Year 2024 Revenue Growth Range to 14%-18%, vs Prior View of 12%-17%; Sees Q2 Revenue Growth of 15%-18%	May. 09	MT
Insulet Corporation Provides Revenue Guidance for the Second Quarter Ending June 30, 2024	May. 09	CI
Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024	May. 09	CI
China trade heats up, UK rates in view	May. 09	RE
Wolfe Upgrades Insulet to Outperform From Peerperform With $200 Price Target	May. 07	MT
Wolfe Research Upgrades Insulet to Outperform From Peer Perform, Price Target is $200	May. 07	MT
US Equity Markets Close Higher Wednesday as Fed Holds Rates Steady	Mar. 20	MT
Insulet Names Ana Maria Chadwick Finance Chief	Mar. 20	MT
Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024	Mar. 20	CI
Insulet Corporation Announces Chief Financial Officer Changes	Mar. 20	CI
3M Board Approves Healthcare Unit Spinoff -- Update	Mar. 08	DJ
Transcript : Insulet Corporation - Special Call	Mar. 08
Insulet Says Trial Shows Omnipod 5 Insulin Delivery System Superior to Pump Therapy	Mar. 08	MT
Insulet Corporation Presents Positive Results from its First Randomized Controlled Trial Showing Improved Glycemic and Patient-Reported Outcomes in Type 1 Diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5)	Mar. 08	CI
Transcript : Insulet Corporation Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 11:35 AM	Mar. 05

Chart Insulet Corporation

Duration

Period

More charts

Company Profile

Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (95.6%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (4.4%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). By the end of 2022, the group will have 2 production sites located in the United States and in China. The United States accounts for 72.2% of net sales.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Insulet Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

181.1 USD

Average target price

233.5 USD

Spread / Average Target

+28.95%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
INSULET CORPORATION	-16.55%	12.68B
ABBOTT LABORATORIES	-4.77%	182B
MEDTRONIC PLC	+4.10%	114B
BECTON, DICKINSON AND COMPANY	-3.85%	67.76B
DEXCOM, INC.	+5.19%	51.91B
CENCORA, INC.	+5.54%	43.23B
HOYA CORPORATION	+6.07%	41.07B
METTLER-TOLEDO INTERNATIONAL, INC.	+23.81%	32.07B
TERUMO CORPORATION	+15.86%	25B
WEST PHARMACEUTICAL SERVICES, INC.	-5.06%	24.35B

Other Medical Equipment, Supplies & Distribution